XGen Pharmaceuticals DJB

What XGen Pharmaceuticals DJB does

XGen Pharmaceuticals DJB, Incorporated is a privately-held, family- and woman-owned generic pharmaceutical manufacturer founded in 1972 (originally as Pharma-Tek) and headquartered at 300 Daniel Zenker Drive in Big Flats/Horseheads, New York. The company produces a portfolio of approximately 20 FDA-approved generic injectable pharmaceuticals — including anti-infectives (Vancomycin, Amphotericin B, Tobramycin, Streptomycin, Lincomycin), oncology products (Eribulin Mesylate, Cyclophosphamide, Dactinomycin, Nelarabine), neurology treatments (Edaravone), and supportive care injectables — distributed exclusively through the Big Three US pharmaceutical wholesalers (Cencora, Cardinal Health, McKesson) plus Morris Dickson into the hospital, clinic, and institutional market.

The company's underlying technology is operational and regulatory rather than digital: a DSCSA-compliant global serialization program using 13-digit SNIs, EPCIS 2.0 standards with AS2 data exchange, NABP Pulse VRS integration for product verification, and EDI capabilities covering standard pharmaceutical transactions (810 Invoice, 844 Chargeback, 845 Contract, 849 Chargeback Reconciliation, 850 Purchase Order, 856 ASN, 997 Acknowledgement). Manufacturing is executed through contract manufacturing organizations (CMOs), with XGen functioning as a specialty distributor and ANDA holder. The company holds NABP Drug Distributor Accreditation (May 2022), FDA compliance, and 20 approved ANDAs.

XGen's business model is B2B pharmaceutical distribution: it acquires/holds ANDAs, sources finished product through CMOs, and sells through wholesalers to US hospitals and clinics at negotiated, quote-based pricing. The strategy targets past-patent molecules with stable volumes and few competitors rather than commodity generics. Leadership is family-controlled: Susan Badia has served as CEO since 2003 (succeeding founder Dan Badia), with Catherine Liles as CAO/Treasurer and J. Robin Liles as COO. The stated objective is 4–6 new product launches per year, with a recently-accelerated cadence including Eribulin Mesylate (April 2026), Edaravone (December 2024), Cyclophosphamide and Desmopressin Acetate (February–March 2024), and Pentamidine (July 2023).

Name

XGen Pharmaceuticals DJB

Legal name

XGen Pharmaceuticals DJB, Incorporated

Website

https://xgenpharmadjb.com

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

101–250 employees

Short description

XGen Pharmaceuticals DJB is a family- and woman-owned generic pharmaceutical manufacturer of 20 FDA-approved injectable products, distributed through Cencora, Cardinal Health, McKesson, and Morris Dickson into US hospital, clinic, and institutional markets from its Big Flats, NY headquarters.

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Generic injectables manufacturing
• Generic pharmaceuticals distribution
• Hospital injectable supply
• ANDA drug products
• Pharmaceutical wholesale distribution

Headquarters

HQ city

Horseheads

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: XGen generates revenue through the sale of generic injectable pharmaceuticals to the hospital/clinic/institutional market. The company focuses on past-patent products with stable volumes and few competitors, distributing primarily in the US market. Their product line includes injectables, anti-infectives, and other acute care medications.
2. Licensing and ANDA Distribution: Revenue generated through asset purchases and licensing of Abbreviated New Drug Applications (ANDAs) and NDAs, joint product development, and product lifecycle management including regulatory support.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

XGen Pharmaceuticals DJB manufactures and distributes a portfolio of FDA-approved generic injectable pharmaceuticals (with additional topicals, oral solids and inhalants) targeting the US hospital, clinic and institutional market. The company holds 20 approved ANDAs, focuses on past-patent products with stable volumes and limited competition, and ships primarily through major pharmaceutical wholesalers and a dedicated National Accounts Team. It is supported by DSCSA-compliant serialization, EPCIS/AS2 data exchange, and full EDI transactional capabilities.

Product overview

XGen Pharmaceuticals DJB is a generic pharmaceutical company offering a portfolio of injectable medications distributed primarily through the hospital/clinic/institutional market in the US. The product portfolio includes anti-infectives (Amphotericin B, Lincomycin, Streptomycin, Tobramycin, Vancomycin), oncology drugs (Cyclophosphamide, Dactinomycin, Eribulin Mesylate, Nelarabine), and other therapeutic categories (AcetaZOLAMIDE, Clonidine, Desmopressin Acetate, Folic Acid, Ibuprofen Lysine, Liothyronine Sodium, Olanzapine, Promethazine, Rocuronium Bromide, Tranexamic Acid, Dehydrated Alcohol). Additional offerings include irrigants/topicals (Neomycin and Polymyxin B Sulfates) and inhalants (Pentamidine Isethionate for Inhalation). The company focuses on acquiring and launching products in stable volume markets with few competitors.

Differentiator

Problem solved

Functional benefit

Products and services

• Eribulin Mesylate Injection Oncology injectable medication - clear, colorless, sterile solution for intravenous administration. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution (0.5 mg/mL). NDC: 39822-2080-1.
• Edaravone Injection Generic therapeutic equivalent of RADICAVA for ALS. Available in 30 mg/100 mL (0.3 mg/mL) 2-pack carton and 60 mg/100 mL (0.6 mg/mL) single vial carton. Positioned as first generic alternative in vial presentation.
• Desmopressin Acetate Injection, USP Available in 40mcg/10mL x 1 vial and 4mcg/mL x 10 vials presentations. Single-dose (4 mcg/1 mL) and multi-dose (40 mcg/10 mL) vials.
• Cyclophosphamide for Injection, USP Oncology injectable medication available with 3-year shelf-life in single-dose vials containing 500 mg, 1 gram or 2 grams of lyophilized powder.
• Pentamidine Isethionate (Injection and Inhalation) Pentamidine Isethionate for Inhalation - generic therapeutic equivalent of Nebupent, single-dose 300 mg vials, 1 vial per carton (NDC: 39822-3030-2). Pentamidine Isethionate for Injection - generic therapeutic equivalent of Pentam 300, single-dose 300 mg vials, 10 vials per carton (NDC: 39822-3050-2).
• Olanzapine for Injection Atypical antipsychotic for treatment of acute agitation associated with schizophrenia and bipolar I mania. 10 mg/vial x 1 vial for intramuscular use only. NDC: 39822-1800-1.
• AcetaZOLAMIDE for Injection, USP Generic injectable pharmaceutical product for the treatment of various conditions including glaucoma, altitude sickness and metabolic alkalosis.
• Amphotericin B for Injection, USP Anti-infective injectable antifungal medication used to treat serious systemic fungal infections.
• Clonidine Hydrochloride Injection Generic injectable pharmaceutical product used for the treatment of hypertension and ADHD, and for pain management.
• Dactinomycin for Injection, USP Oncology injectable chemotherapy medication.
• Dehydrated Alcohol Injection, USP Generic injectable pharmaceutical product used for nerve block procedures and therapeutic neurolysis.
• Folic Acid Injection, USP Generic injectable pharmaceutical product for the treatment of megaloblastic anemia and folate deficiency.
• Ibuprofen Lysine Injection Generic injectable NSAID used in neonatal populations for the treatment of patent ductus arteriosus.
• Lincomycin Injection, USP Anti-infective injectable antibiotic medication.
• Liothyronine Sodium Injection (T3) Generic injectable pharmaceutical product for thyroid hormone replacement therapy.
• Nelarabine Injection Oncology injectable chemotherapy medication for the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
• Promethazine Hydrochloride Injection, USP Generic injectable antihistamine and antiemetic pharmaceutical product.
• Rocuronium Bromide Injection Generic injectable neuromuscular blocking agent used as an adjunct to general anesthesia.
• Streptomycin for Injection, USP Anti-infective injectable aminoglycoside antibiotic medication.
• Tobramycin for Injection, USP Anti-infective injectable aminoglycoside antibiotic medication.
• Tranexamic Acid Injection Generic injectable antifibrinolytic pharmaceutical product used to reduce or prevent bleeding.
• Vancomycin Hydrochloride Injection, USP Anti-infective injectable glycopeptide antibiotic medication for serious gram-positive infections.
• Neomycin and Polymyxin B Sulfates Solution for Irrigation, USP Irrigant/topical pharmaceutical product for urinary bladder irrigation.
• Generic Injectables Portfolio Portfolio of generic injectable pharmaceuticals distributed primarily through the hospital/clinic/institutional market with predominant focus on the US market. Growth areas include oncology, parental nutritional supplements, chronic disease, cardiology and neurology, with 20 approved ANDAs and a goal of 4-6 new product launches per year.

Quantifiable outcome

• 3-5 new products added to portfolio each year
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration12 records

Feature2 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Americares FoundationminorOthers · 29 January 2020XGen made an essential medicine donation to Americares Foundation valued at $2.5 million in January 2020. Americares is a health-focused relief and development organization that saves lives and improves health for people affected by poverty or disaster, delivering clinical services, emergency programs and access to medicine globally.
• Kingsway CharitiesminorOthers · 29 January 2020XGen made an essential medicine donation to Kingsway Charities valued at $2.5 million in January 2020. Kingsway Charities provides humanitarian aid worldwide through Medical Missions, having supported 11,000+ mission teams in 145 countries since 1994.
• Contract Manufacturing Organizations (CMOs)coreStrategic or Co-development PartnerXGen works with CMOs for manufacturing and packaging of finished pharmaceutical products. Serialization requirements mandate 13-digit numeric serial numbers, aggregation at case and bundle levels, and EPCIS data exchange via AS2 connection.
• CencoracoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distributor for XGen products including Eribulin Mesylate Injection. Part of the major distributor network serving US healthcare facilities.
• Cardinal HealthcoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distributor for XGen products. Part of the distribution network for injectables and acute care medications.
• McKessoncoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distributor for XGen products. Serves as key distribution channel for generic injectables to hospital and clinic markets.
• Morris DicksoncoreChannel Partner/ Reseller/ DistributorPharmaceutical distributor for XGen products, distributing to healthcare facilities in their service areas.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Aurobindo Pharma: Indian-headquartered generic manufacturer expanding in US injectable generics. Competes with XGen on cost-competitive injectable molecules and increasingly on specialty injectables.
• Dr. Reddy's Laboratories: Global generics manufacturer with a growing US sterile injectable portfolio and partnerships with major US wholesalers. Comparable on product range and channel strategy.

Direct peers

• Hikma Pharmaceuticals: A leading US-focused generic injectable manufacturer with a comparable hospital-channel portfolio. Direct overlap with XGen in injectable generics, anti-infectives, and US institutional distribution.
• Amphastar Pharmaceuticals: US-based specialty injectable generics manufacturer focused on hospital and clinic channels. Highly comparable in product mix (injectables, oncology, anti-infectives) and go-to-market model.

Broad incumbents

• Fresenius Kabi: Large global player in generic injectable pharmaceuticals serving hospital and clinical nutrition markets. Overlaps with XGen in sterile injectables and US hospital distribution.
• Baxter International: Diversified injectable pharmaceutical and medical device company with strong US hospital presence. Overlaps with XGen on injectable generics and institutional channel access.
• Sandoz (Novartis): World's largest generics manufacturer with a deep injectable portfolio. Competes with XGen across multiple molecules in the US hospital channel but at far greater scale.
• Pfizer CentreOne (Hospira legacy): Pfizer's injectable pharmaceuticals franchise, the legacy Hospira business. Direct overlap with XGen in sterile injectables distributed through US wholesalers.
• Teva Pharmaceutical Industries: Largest generic drug manufacturer globally with broad injectable and specialty portfolio. Indirect overlap with XGen on injectable generics, though Teva's portfolio is far larger and more diversified.
• B. Braun Medical: Global medical device and pharmaceutical company with US injectable pharmaceutical operations. Overlaps with XGen in hospital-channel injectables, irrigation solutions, and clinical nutrition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XGen Pharmaceuticals DJB